Q1 Media Minds Roundtable Panel - What Will 2026 Look Like for Biotech and Healthcare? Post-JPM Journalist Perspectives
Exclusive to T2B Pro and Student members.
If you're not part of Ticket to Biotech, confirm you're eligible, and join as a Pro or Student member before registering for this event:
T2B Intake Form
***If you do not receive your event confirmation within 1 business day of RSVPing (above), check your email spam folder. The automated Luma email includes the Zoom info and cal invite.***
WHAT WILL 2026 LOOK LIKE FOR BIOTECH AND HEALTHCARE? POST-JPM JOURNALIST PERSPECTIVES
The 2026 JPM Healthcare Conference may be over, but for reporters covering biotech and healthcare, it was less a recap moment and more of a reset. This Media Minds Roundtable brings together leading journalists to reflect on the conversations, signals, and omissions they heard in San Francisco and how those insights are already reshaping what they’re reporting on in 2026.
Rather than revisiting company announcements or stock moves, this journalist-led discussion will focus on what changed reporters’ mental models after JPM: which narratives gained credibility, which hype cycles quietly cooled, and which issues now feel unavoidable for the year ahead. Expect candid perspectives on where innovation, capital, regulation, and global competition are colliding and how those forces will define biotech and healthcare coverage in 2026.
Featuring:
Annalee Armstrong, Senior Editor, BioSpace
Max Bayer, Pharma Reporter, Endpoints News
Mandy Jackson, Managing Editor, US Commercial News, Citeline
Why attend — hear:
What journalists stopped chasing, what they’re doubling down on, and which storylines now feel inevitable this year.
Which themes from JPM conversations (global drug development, pricing pressure, AI fatigue vs. traction, China and cross-border biotech, obesity drugs, clinical risk) reporters believe will actually move the industry.
How reporters are increasingly connecting science, policy, geopolitics, and market access — and why siloed storytelling is breaking down.
The questions reporters are asking executives in 2026 that they weren’t asking a year ago, and what earns follow-up coverage versus polite silence.
What didn’t show up at JPM, but matters anyway
MEET OUR GUEST SPEAKERS
Annalee Armstrong, Senior Editor, BioSpace
Annalee Armstrong is an award-winning biopharma journalist covering the business of drug development. She began her career at small newspapers across Western Canada. During the assignment of a lifetime, the Yukon Quest Sled Dog Race, she met her husband in Alaska and eventually moved to the U.S. Since then, Annalee has covered energy, environmental regulations, healthcare and biopharma. Prior to BioSpace, Annalee was senior editor for Fierce Biotech, where she received several awards for her writing and editing. She lives in Ottawa, Ontario, with her husband, two wild boys, an anxious Rhodesian Ridgeback and an indifferent tabby cat.
Max Bayer, Pharma Reporter, Endpoints News
Max Bayer is a pharma reporter at Endpoints News. He joined from Fierce Biotech where he spent more than two years reporting on all corners of the biotech industry. He previously spent more than three years at CBS News, covering the twists and turns of the COVID-19 pandemic, from infection trends to CDC guidelines. A Bay Area native, Max graduated from the University of Wisconsin-Madison in 2018 and now lives in Brooklyn, rooting on northern California sports teams and biking around the borough (with a helmet, of course).
Mandy Jackson, Managing Editor, US Commercial News, Citeline
Mandy Jackson reports on daily biopharma developments, writes feature stories and produces Scrip's Finance Watch column. She covers finance, start-ups, dealmaking, clinical trial results, quarterly earnings reports, commercial competition and corporate strategy. Mandy regularly interviews everyone from big pharma CEOs to biotech start-up founders, enhancing her expertise on industry trends and market dynamics. She also is interested in drug pricing and novel reimbursement strategies, new treatments in areas of true unmet need, diversity in the biopharma industry and novel approaches to drug development. She has been a business reporter since 2000, covering biopharma, biotech law and commercial real estate.